Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Martin Trbušek"'
Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
Autor:
Helena Olbertova, Karla Plevova, Sarka Pavlova, Jitka Malcikova, Jana Kotaskova, Kamila Stranska, Michaela Spunarova, Martin Trbusek, Veronika Navrkalova, Barbara Dvorackova, Nikola Tom, Karol Pal, Marie Jarosova, Yvona Brychtova, Anna Panovska, Michael Doubek, Sarka Pospisilova
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between
Externí odkaz:
https://doaj.org/article/62c7fe3bce37456bb78f5e4434870ef7
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Veronika Navrkalova, Emma Young, Panagiotis Baliakas, Lenka Radova, Lesley-Ann Sutton, Karla Plevova, Larry Mansouri, Viktor Ljungström, Stavroula Ntoufa, Zadie Davis, Gunnar Juliusson, Karin E. Smedby, Chrysoula Belessi, Panagiotis Panagiotidis, Tasoula Touloumenidou, Frederic Davi, Anton W. Langerak, Paolo Ghia, Jonathan C. Strefford, David Oscier, Jiri Mayer, Kostas Stamatopoulos, Sarka Pospisilova, Richard Rosenquist, Martin Trbusek
Publikováno v:
Haematologica, Vol 101, Iss 9 (2016)
Externí odkaz:
https://doaj.org/article/c3d075fc37da4bfbbe723124a9af0818
Autor:
Lesley-Ann Sutton, Viktor Ljungström, Larry Mansouri, Emma Young, Diego Cortese, Veronika Navrkalova, Jitka Malcikova, Alice F. Muggen, Martin Trbusek, Panagiotis Panagiotidis, Frederic Davi, Chrysoula Belessi, Anton W. Langerak, Paolo Ghia, Sarka Pospisilova, Kostas Stamatopoulos, Richard Rosenquist
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Next-generation sequencing has revealed novel recurrent mutations in chronic lymphocytic leukemia, particularly in patients with aggressive disease. Here, we explored targeted re-sequencing as a novel strategy to assess the mutation status of genes w
Externí odkaz:
https://doaj.org/article/32d6b0158569438e91c94271af6b9834
Autor:
Veronika Navrkalova, Ludmila Sebejova, Jana Zemanova, Jana Kminkova, Blanka Kubesova, Jitka Malcikova, Marek Mraz, Jana Smardova, Sarka Pavlova, Michael Doubek, Yvona Brychtova, David Potesil, Veronika Nemethova, Jiri Mayer, Sarka Pospisilova, Martin Trbusek
Publikováno v:
Haematologica, Vol 98, Iss 7 (2013)
ATM abnormalities are frequent in chronic lymphocytic leukemia and represent an important prognostic factor. Sole 11q deletion does not result in ATM inactivation by contrast to biallelic defects involving mutations. Therefore, the analysis of ATM mu
Externí odkaz:
https://doaj.org/article/7151e415765547daba8ee5a8ed2e6964
Autor:
Stanislav Drápela, Miroslav Boudny, Josef Jaroš, Michaela Špunarová, Jan Verner, Prashant Khirsariya, Zuzana Jašková, Kamil Paruch, Yvona Brychtová, Marie Kasparkova, Jana Zemanová, Jiri Mayer, Marek Borsky, Václav Šeda, Jana Černá, Martin Trbušek, Alexandra Oltová, Marek Mráz, Karel Souček
Publikováno v:
Haematologica
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Autor:
Marie Jarošová, Heidi Mocikova, Jan Oppelt, Leos Kren, Vít Procházka, Katerina Machova Polakova, Pavel Burda, Olaf Merkel, Katerina Cerna, Robert Pytlik, Ana-Iris Schiefer, Marek Trneny, Lenka Zlamalikova, Martin Trbušek, Ján Deván, Lenka Kruzova, Ingrid Simonitsch-Klupp, Václav Šeda, Sonali Sharma, Zuzana Prouzová, Andrea Janíková, Katerina Musilova, Andrew G. Evans, Gabriela Pavlasova, Clive S. Zent, Jiri Mayer, Kvetoslava Liskova, Andrea Marečková, Christoph Kornauth, Marek Mráz
Publikováno v:
Blood. 132:2389-2400
Follicular lymphoma (FL) is a common indolent B-cell malignancy with a variable clinical course. An unfavorable event in its course is histological transformation to a high-grade lymphoma, typically diffuse large B-cell lymphoma. Recent studies show
Autor:
Viera Hrabčáková, Marek Borsky, Anna Panovská, Jitka Novotná, Michael Doubek, Petr Muller, Marek Mráz, Jiri Mayer, Martin Trbušek, Yvona Brychtová
Publikováno v:
Leukemia research. 111
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of ritu
Autor:
Miroslav Boudny, Martin Trbušek
Publikováno v:
Klinicka Onkologie. 33
Background: Signal transducer and activator of transcription (STAT) proteins are cytoplasmic tran-scription factors that transmit the signal of cytokines, hormones and growth factors. STAT pro-teins control fundamental cellular processes including su
Autor:
Martin Trbušek, Miroslav Boudny
Publikováno v:
Cancer treatment reviews. 88
Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chro